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Background: Several candidate genes have been identified in relation to lipid 42 
metabolism, and among these, lipoprotein lipase (LPL) and apolipoprotein E (APOE) 43 
gene polymorphisms are major sources of genetically determined variation in lipid 44 
concentrations. This study investigated the association of two single nucleotide 45 
polymorphisms (SNPs) at LPL, seven tagging SNPs at the APOE gene, and a common 46 
APOE haplotype (two SNPs) with blood lipids, and examined the interaction of these 47 
SNPs with dietary factors.  48 
Methods: The population studied for this investigation included 660 individuals from the 49 
Prevention of Cancer by Intervention with Selenium (PRECISE) study who supplied 50 
baseline data. The findings of the PRECISE study were further replicated using 1,238 51 
individuals from the Caerphilly Prospective cohort (CaPS). Dietary intake was assessed 52 
using a validated food-frequency questionnaire (FFQ) in PRECISE and a validated semi-53 
quantitative FFQ in the CaPS. Interaction analyses were performed by including the 54 
interaction term in the linear regression model adjusted for age, body mass index, sex and 55 
country.  56 
Results: There was no association between dietary factors and blood lipids after 57 
Bonferroni correction and adjustment for confounding factors in either cohort. In the 58 
PRECISE study, after correction for multiple testing, there was a statistically significant 59 
association of the APOE haplotype (rs7412 and rs429358; E2, E3, and E4) and APOE 60 
tagSNP rs445925 with total cholesterol (P=4x10-4 and P=0.003, respectively). Carriers of 61 
the E2 allele had lower total cholesterol concentration (5.54± 0.97 mmol/L) than those 62 
with the E3 (5.98± 1.05 mmol/L) (P=0.001) and E4 (6.09± 1.06 mmol/L) (P=2x10-4) 63 
alleles. The association of APOE haplotype (E2, E3, and E4) and APOE SNP rs445925 64 
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with total cholesterol (P=2x10-6 and P=3x10-4, respectively) was further replicated in the 65 
CaPS. Additionally, significant association was found between APOE haplotype and 66 
APOE SNP rs445925 with low density lipoprotein cholesterol in CaPS (P=4x10-4 and 67 
P=0.001, respectively). After Bonferroni correction, none of the cohorts showed a 68 
statistically significant SNP-diet interaction with lipid outcomes.  69 
Conclusion: In summary, our findings from the two cohorts confirm that genetic 70 
variations at the APOE locus influence plasma total cholesterol concentrations, however, 71 
the gene-diet interactions on lipids require further investigation in larger cohorts. 72 
 73 
Keywords: APOE gene, total cholesterol, LDL-C, PRECISE, Caerphilly Prospective 74 
studies 75 
 76 
  77 
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 Background 78 
Cardiovascular diseases (CVD) are common multifactorial conditions 79 
characterized by dyslipidaemia, type 2 diabetes and hypertension [1, 2]. Elevated 80 
triacylglycerol (TAG) and reduced high density lipoprotein cholesterol (HDL-C) 81 
concentrations are associated with an increased risk of developing CVD [3-5]. 82 
Furthermore, several studies have reported that certain genetic variants influence 83 
susceptibility to altered circulating lipid concentrations, leading to an increased risk of 84 
CVD events [6-8]. Genetic variations have been shown to be associated with lipid 85 
outcomes, while dietary factors appear to modulate the effect of such genes on lipid 86 
concentrations [9, 10]. Previous studies have shown that single nucleotide 87 
polymorphisms (SNPs) of the apolipoprotein E (APOE) [6, 11] and lipoprotein lipase 88 
(LPL) [12-14] genes contribute to significant variation in lipid concentrations.  89 
The APOE protein plays a key role in the transport and metabolism of cholesterol 90 
and TAG containing particles by serving as a receptor-binding ligand that mediates the 91 
clearance of dietary derived chylomicrons, and hepatically derived very low density 92 
lipoprotein (VLDL) and their remnants from the circulation [6]. The three most 93 
recognized alleles of the APOE gene are E2, E3 and E4, with carriage of E4 associated 94 
with CVD risk factors and increased low density lipoprotein cholesterol (LDL-C) 95 
concentrations [11, 15, 16], and hence increased CVD risk [17, 18].  96 
Genetic variations in the LPL gene have been reported to be involved with lipid 97 
metabolism and partly explain the phenotypic variation in blood lipid levels [19]. LPL is 98 
a lipolytic enzyme that catalyses hydrolysis of TAG in all of the major classes of TAG-99 
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rich lipoproteins [20]. High enzyme activity is associated with favourable lipid levels, 100 
including relatively low TAG concentrations [21]. The two most widely studied LPL 101 
SNPs, rs328 (S447X) and rs320 (HindIII) [22, 23]. The ‘G’ minor alleles of both the 102 
SNPs, rs328 and rs320, are associated with decreased TAG concentrations and increased 103 
HDL-C concentrations, whereas the opposite association was found for the ‘C’ allele and 104 
‘T’ allele respectively [24-26].  105 
Data from several studies supports the role of genetic factors in lipid metabolism 106 
[27]; however, only a few studies have examined the effects of lifestyle factors such as 107 
diet on the association of polymorphisms with lipid-related outcomes [10, 28, 29]. 108 
Therefore, the present study aimed to investigate the effect of seven APOE tagSNPs 109 
(rs405509, rs769450, rs439401, rs445925, rs405697, rs1160985, and rs1064725), one 110 
APOE haplotype (rs7412 and rs429358), and two commonly studied LPL SNPs (rs328 111 
and rs320) on blood lipid profile in 660 participants (baseline data) from the Prevention 112 
of Cancer by Intervention with Selenium (PRECISE) study. As diet type and intake is 113 
also known to modify lipid levels [30-32], the potential impact of the interaction between 114 
these SNPs and dietary factors on lipid levels was also investigated. To confirm the 115 
findings, the Caerphilly Prospective Study (CaPS; n=1,238) was used as a replication 116 
cohort.   117 
 118 
Material and methods 119 
PRECISE cohort 120 
Participants and methods 121 
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Baseline data of 660 individuals from the PRECISE study, conducted in two 122 
populations [UK (n=468) and Denmark (n=192)] were used for the analysis [33, 34]. 123 
Briefly, study participants were selected from four general practices (study centres) in 124 
various areas of the UK that were affiliated with the Medical Research Council General 125 
Practice Research Framework (MRC GPRF). Between June 2000 and July 2001, research 126 
nurses recruited similar numbers of men and women from each of three age groups: 60–127 
64, 65–69 and 70–74 years. The Danish participants were men and women recruited from 128 
the same three age groups from the County of Funen in Denmark.  129 
The UK study obtained approval from the appropriate UK Local Research Ethics 130 
Committees [South Tees (ref: 99/69), Worcestershire Health Authority (ref: LREC 131 
74/99), Norwich District (ref: LREC 99/ 141), Great Yarmouth and Waveney (under 132 
reciprocal arrangements with Norwich District LREC)], and the participants provided 133 
written informed consent. The regional Danish Data Protection Agency and Scientific 134 
Ethical Committees of Vejle and Funen counties approved the Danish study (Journal 135 
number. 19980186).  136 
Dietary information  137 
Information about each participant’s usual dietary intake was obtained using 138 
validated EPIC food frequency questionnaires (FFQ) [35]. Total energy intake and 139 
macronutrient composition were analysed using the FETA software program [36].  140 
Anthropometric measurements and biochemical analysis   141 
Body mass index (BMI) was calculated as body weight in kilograms divided by 142 
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height in square metres (kg/m2). Participants provided non-fasting blood samples for 143 
biochemical analysis and these samples were stored at −80°C. Total cholesterol and 144 
HDL-C concentrations in lithium-heparin plasma were measured using an Architect 145 
c16000 analyser (Abbott) with dedicated reagents. Measurements were performed by 146 
enzymatic colorimetric analysis. Traceability for total cholesterol and HDL-C was 147 
ensured through participation in the National Reference System for Cholesterol 148 
(NRS/CHOL), as established by the Clinical and Laboratory Standards Institute, with 149 
isotope dilution-MS used as the reference method, and reference material taken from the 150 
National Institute of Standard and Technology. Evidence of equivalence in the analytical 151 
performance of the cholesterol-oxidase assays performed in the UK and Denmark from a 152 
comparison of total cholesterol on forty-four serum samples which produced a limit of 153 
variation of 2% [33].  154 
SNP selection: 155 
The APOE gene is located on chromosome 19q13.32. It comprises four exons, 156 
which are transcribed into the APOE mRNA which is 1,180 nucleotides long. The seven 157 
tagSNPs for the APOE gene were chosen based on International HapMap Phase II 158 
collected from individuals of Northern and Western European ancestry (CEU) (HapMap 159 
Data release 27 Phase 2+3, Feb 09, NCBI B36 assembly, dbSNP b126). The Haploview 160 
software V3.3 (http://www.broadinstitute.org/haploview/haploview-downloads) was used 161 
to assess the linkage disequilibrium between SNPs. Tagger software was used to select 162 
tagSNPs with the ‘pairwise tagging only’ option. Two criteria were used to filter the 163 
SNPs included in the analysis, minor allele frequency ≥5% and Hardy–Weinberg 164 
equilibrium P-value >0.01. In total, seven tagSNPs [rs405509 (G>T), rs1160985 (C>T), 165 
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rs769450 (G>A), rs439401 (C>T), rs445925 (G>A), rs405697 (G>A), and rs1064725 166 
(T>G)] representing the entire common genetic variations across the APOE gene were 167 
selected for the study. The APOE haplotype/SNPs [6, 11, 37-44] and LPL [12, 13] SNPs 168 
were chosen based on their previous association with various lipid outcomes.  169 
DNA isolation and genotyping  170 
The genotyping for the selected SNPs using a KASP assay with a competitive 171 
allele-specific PCR assay® was performed on DNA samples by LGC Genomics 172 
(Hoddesdon, Herts, UK).  The eleven SNPs were in Hardy Weinberg Equilibrium (HWE) 173 
(P>0.05 for all comparisons) (Supplementary Table 1). 174 
 175 
Caerphilly Prospective Study (CaPS) 176 
Participants and methods 177 
The CaPS was used to replicate the findings from the PRECISE study. The phase 178 
1 (July 1979 to September 1983) recruitment for the CaPS included 2,512 men aged 45-179 
59 years who were living in the town of Caerphilly and five of its adjacent villages in the 180 
UK; these participants were followed up at regular intervals [45, 46]. The follow-up data 181 
collection included periods from 1984 to1988 (phase 2), from 1989 to 1993 (phase 3), 182 
from 1993 to 1997 (phase 4), and from 2002 to 2005 (phase 5). For the current study, the 183 
data analysed were taken from phase 3 (n=1,238), which had the maximum number of 184 
samples and variables appropriate to this analysis (total cholesterol and dietary 185 
information), and from phase 5 (n=529) (HDL-C and LDL-C). Ethical approval was 186 
obtained from the South Wales Research Ethics Committee D, and each subject provided 187 
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written informed consent. 188 
Dietary information  189 
Participants completed validated semi-quantitative FFQ in phase 3 [47, 48]. The 190 
FFQ included 50 typical food items in the British diet in order to estimate the mean daily 191 
energy intake and macronutrients and micronutrients consumption.   192 
Anthropometric measurements and biochemical analysis   193 
Height and weight was recorded in order to calculate the BMI. Height was 194 
measured on a stadiometer and weight was measured on a beam balance. Plasm prepared 195 
from blood samples taken after an overnight fast were transported at 4°C to the 196 
laboratories on the day of venepuncture. Total cholesterol and HDL-C, LDL-C 197 
concentrations were measured using enzymatic procedures [49]. and the LDL-C levels 198 
were calculated using the Friedewald Formula [50]. 199 
DNA isolation and genotyping  200 
DNA was extracted from blood samples collected during the period 1992–1994. 201 
SNP information was obtained from the Illumina Cardio Metabochip, which includes 202 
data on 200,000 SNPs from regions previously identified for associations with risk 203 
factors for cardiometabolic disease [51]. Imputation was conducted against the 1000-204 
genomes reference panel, providing information on approximately two million typed or 205 
imputed SNPs. Duplicate samples were genotyped to compute the error rate. Quality 206 
control on genotyped samples has been previously reported [52] and the SNPs had a call 207 
rate of >98%. The SNPs were in HWE (P>0.05) (Supplementary Table 1). 208 
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 209 
Statistical analysis  210 
Statistical analysis was performed using the SPSS software package, version 22.0. The 211 
data were presented as mean ± standard deviation (SD) in Tables 1 and 3 and beta 212 
regression coefficients and standard error (SE) were presented in Tables 2, 4, and 5. 213 
Independent t-test was used to compare means between men and women at baseline in 214 
the PRECISE cohort (Table 1). Univariate linear regression analysis was applied to test 215 
for association of the SNPs with total cholesterol and HDL-C, controlling for age, sex, 216 
BMI and country. SNP-diet interactions on total cholesterol and HDL-C were 217 
investigated using a univariate general linear model. In this model, total cholesterol and 218 
HDL-C were the dependent variables, SNPs were fixed factors, and dietary factors (fat 219 
energy %, protein energy %, carbohydrate energy %), sex, age BMI, and country were 220 
covariates. The dominant model was applied for all SNPs with minor allele frequency 221 
≤0.3 and the additive model applied for SNPs with minor allele frequency ≥0.4. For 222 
analytical purposes, the six APOE genotype groups (E2/E2, E2/E3, E3/E3, E3/E4, E4/E4, 223 
and E2/E4) were classified into three groups. The E3/E3 genotype was classified as a 224 
group as it occurs at high frequency in the population (wild type). The E2/E2 and E2/E3 225 
genotypes were combined and presented as E2 carriers. The E3/E4 and E4/E4 genotypes 226 
were also combined, and presented as E4 carriers [29]. Previous studies have shown that 227 
the impact of the E2 allele on serum lipids is greater than that of the E4 allele [17], 228 
therefore, the E2/E4 genotype was excluded from the analysis. The Bonferroni correction 229 
was applied separately for association and interaction analyses. For association between 230 
phenotypic and dietary factors, the Bonferroni-corrected P value was 0.008 (2 lipid 231 
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outcomes* 3 dietary factors) for the PRECISE study and P value was 0.01 for CaPS (total 232 
cholesterol was the only variable available). For association between SNPs and lipids 233 
(PRECISE study), the Bonferroni corrected P value was 0.003 (10 SNPs*2 lipid 234 
outcomes = 20 tests). For interactions (PRECISE study), the Bonferroni corrected P value 235 
was 0.001 (10 SNPs*2 lipid outcomes*3 dietary factors = 60 tests). In the replication 236 
analysis (CaPS cohort), the Bonferroni corrected P value for association was 0.002 (10 237 
SNPs*3 lipid outcomes = 30 tests), while for interactions it was 0.001 (10 SNPs*1 lipid 238 
outcome* 3 dietary factors = 30 tests).  239 
 240 
Results  241 
Participant characteristics  242 
The general characteristics of the participants by sex are presented in Table 1. In 243 
the PRECISE study, women were found to have significantly higher total cholesterol and 244 
HDL-C concentrations than men (P=2.31x10-10 and P= 2.71x10-16, respectively). The 245 
consumption of carbohydrates (P=1.42x10-9) and protein (energy %) (P=5x10-5) were 246 
higher in women than in men, whereas the consumption of fat (energy %) and total 247 
energy intake were lower in women than in men (P=0.01). Characteristics of the 248 
individuals from CaPS are given in Table 1. Elevated total cholesterol levels were 249 
observed among men at phase 3. Dietary-pattern data showed higher consumption of 250 
energy from total fat.    251 
Association between dietary factors and blood lipids 252 
In both the PRECISE and CaPS, there was no association between the dietary 253 
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factors and total cholesterol or high-density lipoprotein after Bonferroni correction and 254 
adjustment for confounding factors (Table 2). 255 
 256 
Table 2: Association between dietary factors and lipids in PRECISE and Caerphilly 257 
Prospective studies 258 
PRECISE study 
Association between dietary factors and total cholesterol 
Fat total energy % intake 
Beta (± S.E),  
Passociation  
Protein total energy % 
intake 
Beta (± S.E),  
Passociation 
Carbohydrate total energy % 
intake 
Beta (± S.E),  
Passociation 
0.01 (0.01) 
0.47 
-0.01 (0.01) 
0.13 
-0.004 (0.01) 
0.40 
Association between three dietary factors and HDL-C high density lipoprotein 
Fat total energy % intake Protein total energy % 
intake 
Carbohydrate total energy % 
intake 
-0.002 (0.002) 
0.29 
-0.002 (0.004) 
0.59 
-0.004 (0.002) 
0.02 
Caerphilly Prospective study 
Association between three dietary factors and total cholesterol 
Fat total energy % intake 
Beta (± S.E),  
Passociation 
Protein total energy % 
intake 
Beta (± S.E),  
Passociation 
Carbohydrate total energy % 
intake 
Beta (± S.E),  
Passociation  
0.01 (0.004) 
0.06 
-0.01 (0.01) 
0.26 
-0.01 (0.004) 
0.17 
HDL-C, high density lipoprotein cholesterol.  259 
P values were obtained using linear regression adjusted for age, sex, body mass index and 260 
country. 261 
 262 
 263 
Genotypes and serum lipid levels in the PRECISE study 264 
As shown in Table 3, of the seven tagSNPs at APOE, tagSNP rs445925 was 265 
significantly associated with total cholesterol (P=0.003) after correction for multiple 266 
testing. The ‘A’ allele carriers (5.65± 0.98 mmol/L) had 5% lower levels of total 267 
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cholesterol than GG homozygotes (5.99± 1.06 mmol/L).  268 
The levels of HDL-C were significantly different among the LPL SNP genotypes, 269 
rs328 (P=0.04) and rs320 (P=0.02), where the carriers of the ‘G’ minor allele of both 270 
SNPs had higher levels of HDL-C (1.68 ± 0.41 mmol/L for rs328 and 1.66 ±0.40 mmol/L 271 
for rs320) than CC homozygotes (rs328) and TT homozygotes (rs320) (1.61 ± 0.38 and 272 
1.60 ±0.39 mmol/L) respectively. However, these associations were not statistically 273 
significant after Bonferroni correction.  274 
APOE haplotype and serum lipid levels in the PRECISE study 275 
The effects of APOE haplotypes (E2, E3, and E4) on serum lipids are shown in 276 
Table 3. These haplotypes (E2, E3, and E4) were significantly associated with total 277 
cholesterol (P=4x10-4) after correction for multiple testing. The carriers of the E2 allele 278 
(5.54± 0.97 mmol/L) had lower total cholesterol concentrations than the carriers of the 279 
E3 (P=0.001) (5.98± 1.05 mmol/L) and E4 alleles (6.09± 1.06 mmol/L) (P=2x10-4).   280 
Interactions between genotypes and dietary factors on serum lipid in the PRECISE study 281 
None of the dietary factors significantly interacted with the APOE SNPs, 282 
haplotypes and LPL SNPs with plasma lipids after correction for multiple testing (P 283 
>0.001) (Table 4).  284 
Replication analysis: Effect of SNPs at APOE and LPL on serum lipids in the CaPS 285 
The associations of APOE and LPL SNPs with blood lipids in the CaPS are 286 
presented in Table 3. The association of APOE haplotype (E2, E3, and E4) and APOE 287 
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SNP rs445925 with total cholesterol (P=2x10-6 and P=3x10-4, respectively) was 288 
replicated. The ‘A’ allele carriers of APOE SNP rs445925 had lower total cholesterol 289 
(5.96±1.24 mmol/l) than ‘GG’ genotypes (6.24±1.08 mmol/L). In the APOE haplotype 290 
analysis, the carriers of the E2 allele had 5% and 14% lower total cholesterol than carriers 291 
of the E3 (P=4x10-4) and E4 alleles (P=3x10-6), respectively. Additionally, significant 292 
association was seen between APOE haplotypes (E2, E3, and E4) and APOE SNP 293 
rs445925and LDL-C (P=4X10-4, 0.001, respectively). 294 
There was an interaction between fat (% energy) and APOE haplotype (E2, E3, 295 
and E4) on total cholesterol (P=0.038) in CaPS. However, after correction for multiple 296 
testing, all the SNP-diet interactions were consistent with chance variation (Table 5). 297 
 298 
Discussion  299 
Our findings demonstrated significant associations between the APOE haplotype 300 
(E2, E3, and E4) and APOE SNP rs445925 with total plasma cholesterol and LDL-C 301 
(only CaPS) concentration, which were further replicated in an independent UK 302 
Caucasian cohort. The levels of total cholesterol were significantly lower in carriers of 303 
the APOE E2 allele and the ‘A’ allele of the SNP rs445925 than carriers of E3, E4 and 304 
‘GG’ genotype of the APOE SNP rs445925, respectively. Given that our findings confirm 305 
that genetic polymorphisms of APOE influence the inter-individual variation in total 306 
plasma cholesterol, a marker of dyslipidemia, changes in dietary consumption to reduce 307 
disease susceptibility could be implemented for individuals at genetic risk. 308 
  The effects of APOE polymorphisms on lipid concentrations have previously been 309 
investigated in different ethnic groups [11, 53, 54] and studies have shown that the APOE 310 
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gene variants contributed to 7% variability in total cholesterol  [55]. The results of the 311 
current study were in line with previously reported findings that APOE haplotypes (E2, 312 
E3, and E4) are associated with serum total cholesterol and LDL-C, with E4 carriers 313 
associated with increased concentrations compared with E3/E3 wildtype and particularly 314 
E2 carriers [16, 53, 56]. One of the primary roles of APOE is binding the low density 315 
lipoprotein receptor (LDLR) and the LDLR-related protein, to facilitate cellular uptake of 316 
lipoprotein particles [57]. The three alleles, E2, E3, and E4, differ in their amino-acid 317 
sequences, resulting in functional differences in receptors-binding affinity. Amino-acid 318 
sequences of the E2 allele have lower binding affinity than those of the E3 and E4 alleles, 319 
causing decreased hepatic VLDL and chylomicron remnants clearance, thus reducing the 320 
uptake of postprandial lipoprotein particles [57]. Furthermore, it could be postulated that 321 
increase in apoE TAG-rich lipoproteins in E4 carriers could possibly increase the affinity 322 
to bind LDL-receptors resulting in decreased uptake of LDL and increased circulating 323 
plasma cholesterol [58]. E2 carriers also have an impaired conversion of the VLDL 324 
particles to LDL-C compared to E4 carriers [59], who have a higher rate of VLDL 325 
catabolism [60], which explains in part the lower total cholesterol and LDL-C in E2 allele 326 
carriers.  327 
Furthermore, our study highlights an association between APOE SNP rs445925, 328 
which is one of the selected tagSNPs within the APOE gene, and total cholesterol. The 329 
SNP rs445925 has not been extensively studied, however, a genome-wide association 330 
study showed a significant association between SNP rs445925 and LDL-C levels in 3,644 331 
black and white individuals from the US and Europe [61]. In addition, previous genome-332 
wide linkage and association studies have shown linkage disequilibrium (LD) between 333 
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APOE SNPs rs7412 and rs445925 [62] and between ‘A’ allele carriers at SNP rs445925 334 
and E2 haplotype [63], respectively, which could explain in part a similar function in 335 
cholesterol synthesis. It is also possible that A’ allele carriers of the SNP rs445925 might 336 
exhibit lower conversion of the VLDL particles to LDL-C which could have resulted in 337 
the decreased rate of LDL formation and hence lowered the total cholesterol 338 
concentrations [63].   339 
Besides genetic associations, our study also identified an interaction of APOE 340 
haplotypes (E2, E3, and E4) with intake from fat (%) on total cholesterol in the CaPS, 341 
where, among those who consumed a low-fat diet (%), individuals carrying the E2 allele 342 
had significantly lower total cholesterol concentrations than to E4 allele carriers. 343 
However, this interaction was not statistically significant after correction for multiple 344 
testing. A previous study has examined the response of APOE genotype to fat intake in 345 
45 individuals using a prospective design, where after consumption of a lower-fat-346 
cholesterol diet (34% fat, 265 mg/day) according to modified National Cholesterol 347 
Education program there was a significant reduction in total cholesterol by 14%, 9%, and 348 
4% in E4/E4, E3/E4, and E3/E3 genotypes, respectively [64]. Another study showed that 349 
the response to a diet high in cholesterol increases total cholesterol in E3 and E4 350 
compared to E2 allele carries in a study comprising 29 healthy men [65]. By contrast, a 351 
cross sectional study in European Caucasians (n=996) reported that E2 allele carriers had 352 
lower total cholesterol levels, but there were no reported between interactions between 353 
saturated fatty acids and total cholesterol [66]. Given that the previous studies have given 354 
inconsistent results and have used various types of fatty acids, replication of our gene-diet 355 
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interaction finding in a large well-designed randomized controlled trial is highly 356 
warranted.  357 
Previous studies have shown that the minor allele of LPL SNP rs328 enhance 358 
lipolytic activity [12]. Increased activity of LPL results in enhance clearance of TAG 359 
from the circulation, and  associated with higher HDL-C concentrations [67]. The LPL 360 
SNP rs320 (HindIII) is in LD with rs328 (S447X) and they have been shown to have 361 
similar effects on HDL-C, where minor allele was reported to increase HDL-C [24, 68]. 362 
In our study, in accordance with findings from other studies, there were associations 363 
between LPL SNPs, rs320 and rs328, and HDL-C concentrations, where common 364 
homozygotes of both SNPs had lower HDL-C [22-24, 26]. However, in our study, these 365 
associations were no longer statistically significant after Bonferroni correction. 366 
Furthermore, there were no significant LPL SNP-diet interactions with HDL-C or total 367 
cholesterol concentrations in either cohort. To date, there has only been one study that 368 
has shown an interaction between LPL rs328 and total fat intake on HDL-C in 8,764 369 
individuals from the US population, where high fat intake associated with increase HDL-370 
C in CC homozygotes and CG heterozygotes carriers [28]. One of the main reasons we 371 
did not identify a significant interaction may be our small sample size; however, we 372 
cannot rule out an effect of differences in dietary fat sources between European and the 373 
US population. 374 
The present study has some limitations. Importantly, some lipid-related outcomes, 375 
such as LDL-C and TAG concentrations, were not measured in the PRECISE study. The 376 
PRECISE study was also conducted in two populations, a UK cohort and a Danish 377 
cohort, which used different food frequency questionnaires and this might have 378 
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introduced measurement bias, even though the current results were adjusted for country 379 
in the regression analysis to avoid confounding. Another possible limitation is the use of 380 
a cross-sectional design (in both studies) to investigate genetic effects at a single point in 381 
time, whereas a longitudinal analysis design would have captured the genetic effects on 382 
lipid outcomes over a specific time period. The effect-size of the minor allele of some of 383 
the studied SNPs was relatively small, and hence a large sample size is required to detect 384 
reliably detect any interaction between SNPs and dietary factors. Despite the fact that this 385 
study was not adequately powered to detect such an interaction, it was sufficiently 386 
powered to detect the main effects (i.e., associations). Significant gene-diet interactions 387 
were identified, however these did not reach the Bonferroni-corrected P value (P=0.001) 388 
and hence need to be confirmed in larger cohorts. This study is strengthened by the fact 389 
that it is the first study to investigate the role of tagSNPs at the APOE gene in relation to 390 
dietary factors and lipid outcomes. The fact that genetic associations from the PRECISE 391 
study were replicated in another Caucasian cohort (CaPS) confirms the validity of our 392 
findings. Additionally, CaPS was based on a cohort with a very high response rate, and is 393 
therefore closely representative of the general population.  394 
Conclusion 395 
Our study, carried out in two Caucasian populations, confirmed that genetic 396 
variations at the APOE gene locus influence plasma lipid concentrations. Thus, our 397 
results suggest that APOE gene variants affect risk of dyslipidemia in individuals who 398 
carry the E4 risk allele and GG genotype at SNP rs445925. Future studies with a larger 399 
sample size examining tagSNPs at APOE, particularly prospectively genotyped dietary 400 
intervention studies are required to confirm the gene-diet interactions identified in our 401 
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study. 402 
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Figure legend: 
 
Figure 1 Association of APOE haplotypes (E2, E3, and E4) with total cholesterol 
concentrations in the Prevention of Cancer by Intervention with Selenium (PRECISE) 
study and Caerphilly Prospective study (CaPS). E2 allele carriers have significantly lower 
levels of total cholesterol than E3 (P=0.001 and P=4x10-4 in the PRECISE and CaPS, 
respectively) and E4 (P=2x10-4 and P=3x10-6 in the PRECISE and CaPS, respectively) 
allele carriers.   
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Table 1: Baseline characteristics of the PRECISE and Caerphilly Prospective study 
participants  
 PRECISE study Caerphilly 
Prospective 
study (CaPS) 
Characteristics Men  
(N=248 UK, 95 Danish) 
Women  
(N=220 UK, 97 
Danish) 
P value Men  
(N=1,238) 
 Age (years) 67 ± 4 67± 4 0.12 62± 4 
Body mass index (kg/m2) 27.2± 4.9 27.3± 4.9 0.82 26.8± 3.7 
Total Cholesterol (mmol/L) 5.6± 0.9 6.2± 1.1 2.31x10-10 6.1± 1.1 
High density lipoprotein 
cholesterol  (mmol/L)* 
1.5± 0.3 1.7± 0.4 2.71x10-16 1.3± 0.3 
Protein intake (total energy 
%) 
17.6± 3.7 18.8± 3.7 5X10-5 14.9± 2.7 
Carbohydrate intake (total 
energy %) 
42.8± 13.3 48.2± 8.7 1.42x10-9 48.4± 7.5 
Fat intake (total energy %) 35.3± 7.1 33.9± 6.9 0.01 36.5± 6.9 
Total energy intake (kcal) 2256 ± 658 1992± 613 2.63x10-7 1964 ± 625 
Total energy intake (MJ) 9.4± 2.7 8.3± 2.6 2.63x10-7 8.2± 2.6 
Data shown are represented as means ± SD, wherever appropriate. P values are for the 
differences in the means between men and women. P values were calculated by using 
independent t-test.  
*For CaPS, HDL-C levels were obtained from phase 5 while all other variables were 
obtained from phase 3. 
